DoMore Diagnostics is a Norwegian company developing and commercializing deep learning algorithms to guide personalized cancer treatment decisions. Colorectal cancer is the lead indication with a CE-marked product and publications in The Lancet and The Lancet Oncology. The algorithms are applied on digital H&E-stained whole slide images from resected tumor tissue and can predict outcomes in cancer patients. The company is a spin-out from a large research collaboration between Oslo University Hospital and University of Oxford, and there are ongoing collaborations with leading research groups in Europe, Japan, and Australia.
